BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD 211.20
-8.20 (-3.74%)
Aug 14, 2026, 4:08 PM HKT
BeOne Medicines AG Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 6,129 | 5,343 | 3,810 | 2,459 | 1,416 | 1,176 |
Revenue Growth | 34.35% | 40.23% | 54.96% | 73.65% | 20.37% | 280.83% |
Gross Profit Gross Profit Growth | 5,448 | 4,674 | 3,216 | 2,079 | 1,129 | 1,011 |
Operating Income Operating Income Growth | 923.1 | 447.14 | -568.2 | -1,208 | -1,790 | -1,439 |
Net Income Net Income Growth | 655.71 | 286.93 | -644.79 | -881.71 | -2,004 | -1,458 |
Earnings Per Share EPS Growth | 5.59 | 2.47 | -6.12 | -8.45 | -19.43 | -15.71 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
BRUKINSA BRUKINSA Growth | 4,529 | 3,928 | 2,644 | 1,290 | 564.65 | 217.99 |
TEVIMBRA TEVIMBRA Growth | 807.37 | 737.3 | 620.84 | 536.62 | 422.89 | 255.12 |
XGEVA XGEVA Growth | 348.66 | 305.98 | 224.4 | 92.83 | 63.4 | 45.96 |
BLINCYTO BLINCYTO Growth | 125.3 | 104.22 | 74.33 | 54.34 | 36.11 | 12.52 |
KYPROLIS KYPROLIS Growth | 67.95 | 74.97 | 66.17 | 39.8 | 13.7 | - |
POBEVCY POBEVCY Growth | 44.17 | 47.4 | 53.51 | 56.55 | 38.12 | 1.35 |
REVLIMID REVLIMID Growth | - | - | 36.03 | 76.02 | 79.05 | 70.07 |
Other Product Other Product Growth | - | - | 60.04 | 43.3 | 36.7 | 7.74 |
Collaboration Collaboration Growth | 90.39 | 60.97 | 30.7 | 268.93 | 161.31 | 542.3 |
Revenue (Total) Revenue (Total) Growth | 6,129 | 5,343 | 3,810 | 2,459 | 1,416 | 1,176 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5,098 | 4,548 | 2,627 | 3,172 | 4,535 | 6,621 |
Total Debt Total Debt Growth | 2,050 | 2,000 | 1,080 | 930.19 | 596.68 | 694.64 |
Net Cash (Debt) Net Cash Growth | 3,049 | 2,548 | 1,548 | 2,242 | 3,938 | 5,926 |
Net Cash Growth | 76.18% | 64.63% | -30.96% | -43.08% | -33.54% | 44.94% |
Net Cash Per Share Net Cash Per Share Growth | 26.41 | 22.46 | 14.70 | 21.47 | 38.19 | 63.87 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,484 | 1,128 | -140.63 | -1,157 | -1,497 | -1,299 |
Capital Expenditures CapEx Growth | -153.87 | -185.84 | -492.66 | -561.9 | -325.43 | -262.94 |
Free Cash Flow Free Cash Flow Growth | 1,330 | 941.74 | -633.29 | -1,719 | -1,822 | -1,562 |
Free Cash Flow Growth | 443.29% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 88.89% | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% |
Operating Margin | 15.06% | 8.37% | -14.91% | -49.12% | -126.40% | -122.31% |
Pretax Margin | 14.16% | 7.80% | -13.99% | -33.59% | -138.50% | -122.30% |
Profit Margin | 10.70% | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% |
FCF Margin | 21.70% | 17.63% | -16.62% | -69.93% | -128.68% | -132.76% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 60.29 | 117.17 | - | - | - | - |
P/FCF Ratio | 29.72 | 35.70 | - | - | - | - |
PS Ratio | 6.45 | 6.29 | 5.16 | 7.67 | 16.13 | 23.67 |